3,3′-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 649-660

  Zhang, Zhengping ^a   Gao, Zhongfei ^a   Hu, Wei ^a   Yin, Shan ^a   Wang, Chunming ^b   Zang, Yuhui ^a   Chen, Jiangning ^a   Zhang, Junfeng ^a   Dong, Lei ^a,b  

^a NANJING UNIVERSITY   (China)

^b University of Macau   (Macao)

Author keywords

3,3 Diindolylmethane; AP 1; hepatic stellate cells; Liver fibrosis; miR 21; Smad; TGF

Indexed keywords

3,3' DIINDOLYLMETHANE; ALPHA SMOOTH MUSCLE ACTIN; ANTAGOMIR; ANTAGOMIR 21; COLLAGEN; COLLAGEN TYPE 1; MICRORNA 21; SMAD2 PROTEIN; SMAD3 PROTEIN; THIOACETAMIDE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; 3,3'-DIINDOLYLMETHANE; ACTA2 PROTEIN, MOUSE; ACTIN; INDOLE DERIVATIVE; MICRORNA; MIRN21 MICRORNA, MOUSE; MIRN21 MICRORNA, RAT; OLIGONUCLEOTIDE; RECEPTOR REGULATED SMAD PROTEIN; SMOOTH MUSCLE ACTIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; COLLAGEN METABOLISM; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER FIBROSIS; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STELLATE CELL; 3; 3′-DIINDOLYLMETHANE; ANIMAL; AP-1; CELL LINE; CELL PROTECTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL LIVER CIRRHOSIS; GENETIC TRANSFECTION; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; METABOLISM; MIR-21; MOUSE; PATHOLOGY; PHOSPHORYLATION; SMAD; TGF-Β;

3; 3′-DIINDOLYLMETHANE; AP-1; HEPATIC STELLATE CELLS; LIVER FIBROSIS; MIR-21; SMAD; TGF-Β;

ACTINS; ANIMALS; CELL LINE; COLLAGEN TYPE I; CYTOPROTECTION; DOWN-REGULATION; HEPATIC STELLATE CELLS; INDOLES; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICE, INBRED ICR; MICRORNAS; OLIGONUCLEOTIDES; PHOSPHORYLATION; RATS; SIGNAL TRANSDUCTION; SMAD PROTEINS, RECEPTOR-REGULATED; THIOACETAMIDE; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84884580550     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12323     Document Type: Article

References (43)

1. Beaven SW, Wroblewski K, Wang J, Hong C, Bensinger S, Tsukamoto H, et al. (2011). Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 140: 1052-1062.
2. Chung AC, Dong Y, Yang W, Zhong X, Li R, Lan HY, (2013). Smad7 suppresses renal fibrosis via altering expression of TGF-β/Smad3-regulated microRNAs. Mol Ther 21: 388-398.
3. Dong L, Xia S, Gao F, Zhang D, Chen J, Zhang J, (2010). 3,3′-Diindolylmethane attenuates experimental arthritis and osteoclastogenesis. Biochem Pharmacol 79: 715-721.
4. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, et al. (2003). Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 125: 178-191.
5. Frezzetti D, De Menna M, Zoppoli P, Guerra C, Ferraro A, Bello AM, et al. (2011). Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30: 275-286.
6. Friedman SL, (1993). Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 328: 1828-1835.
7. Friedman SL, (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
8. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K, et al. (2008). miR-21 gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 378: 492-504.
9. George J, Roulot D, Koteliansky VE, Bissell DM, (1999). In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 96: 12719-12724.
10. Hernandez-Gea V, Friedman SL, (2011). Pathogenesis of liver fibrosis. Annu Rev Pathol 6: 425-456.
11. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. (2008). Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14: 419-427.
12. Jiang W, Yang CQ, Liu WB, Wang YQ, He BM, Wang JY, (2004). Blockage of transforming growth factor beta receptors prevents progression of pig serum-induced rat liver fibrosis. World J Gastroenterol 10: 1634-1638.
13. Jin Y, (2011). 3,3′-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation. Mol Cell Biochem 358: 345-354.
14. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
15. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, et al. (1990). Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 10: 1492-1497.
16. Kim YH, Kwon HS, Kim DH, Shin EK, Kang YH, Park JH, et al. (2009). 3,3′-Diindolylmethane attenuates colonic inflammation and tumorigenesis in mice. Inflamm Bowel Dis 15: 1164-1173.
17. Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, et al. (2010). Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138: 347-359.
18. Krichevsky AM, Gabriely G, (2009). miR-21: a small multi-faceted RNA. J Cell Mol Med 13: 39-53.
19. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T, (2003). New microRNAs from mouse and human. RNA 9: 175-179.
20. Lee W, Mitchell P, Tjian R, (1987). Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49: 741-752.
21. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. (2010). miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 207: 1589-1597.
22. Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, et al. (2011). Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 55: 612-625.
23. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
24. McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S, (2006). 3,3′-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J Surg Res 132: 208-213.
25. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS, et al. (2010). Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 90: 1727-1736.
26. Melkamu T, Zhang X, Tan J, Zeng Y, Kassie F, (2010). Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 31: 252-258.
27. Mendell JT, Olson EN, (2012). MicroRNAs in stress signaling and human disease. Cell 148: 1172-1187.
28. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H, (2000). Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 32: 247-255.
29. Okino ST, Pookot D, Basak S, Dahiya R, (2009). Toxic and chemopreventive ligands preferentially activate distinct aryl hydrocarbon receptor pathways: implications for cancer prevention. Cancer Prev Res (Phila) 2: 251-256.
30. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H, (1999). Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 96: 2345-2349.
31. Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D, et al. (2009). 3,3′-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res 69: 4468-4475.
32. Riby JE, Xue L, Chatterji U, Bjeldanes EL, Firestone GL, Bjeldanes LF, (2006). Activation and potentiation of interferon-gamma signaling by 3,3′-diindolylmethane in MCF-7 breast cancer cells. Mol Pharmacol 69: 430-439.
33. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA, (2002). Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35: 762-771.
34. Schmierer B, Hill CS, (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8: 970-982.
35. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA, (2001). The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34: 89-100.
36. Shaulian E, Karin M, (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136.
37. Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G, D'Esposito M, et al. (2009). An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 28: 73-84.
38. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984.
39. Vogel S, Piantedosi R, Frank J, Lalazar A, Rockey DC, Friedman SL, et al. (2000). An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res 41: 882-893.
40. Wang XW, Heegaard NH, Orum H, (2012). MicroRNAs in liver disease. Gastroenterology 142: 1431-1443.
41. Weiskirchen R, Gressner AM, (2005). Isolation and culture of hepatic stellate cells. Methods Mol Med 117: 99-113.
42. Zhang C, Ding Z, Suhaimi NA, Kng YL, Zhang Y, Zhuo L, (2009). A class of imidazolium salts is anti-oxidative and anti-fibrotic in hepatic stellate cells. Free Radic Res 43: 899-912.
43. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY, (2011). Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 22: 1668-1681.